Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ballentine

Showing results (21-30 of 451) with videos related to

Pageof 46
Sort By:
Journal of the National Cancer Institute|April 20, 2006
Assessing risk: does this patient have prostate cancer?H Ballentine Carter
The Journal of Urology|March 2, 2019
Editorial CommentH Ballentine Carter
European Urology|July 15, 2014
Reducing prostate cancer deaths: unsupported speculation about the androgen deprivation hypothesisH Ballentine Carter
Journal of the National Cancer Institute. Monographs|December 29, 2012
Active surveillance for prostate cancer: an underutilized opportunity for reducing harmH Ballentine Carter
The Johns Hopkins Medical Letter Health After 50|January 31, 2008
Consultation corner. Prostate screening: refining what PSA levels meanH Ballentine Carter
Urology|February 1, 2003
Informed consent for prostate-specific antigen screeningH Ballentine Carter
Urology|July 2, 2009
Editorial commentH Ballentine Carter
Oncology (Williston Park, N.Y.)|April 8, 2014
Baseline PSA testing for men in their 40s: testing in average-risk men aged 40 to 50 years should not be routinely performedH Ballentine Carter
Current Opinion in Urology|February 19, 2015
Aligning evidence and practice: future research needs to increase utilization of active surveillance for favorable risk prostate cancerH Ballentine Carter
The Journal of Urology|August 21, 2002
Re: long-term followup after laparoscopic radical nephrectomyH Ballentine Carter
Pageof 46

Showing results (21-30 of 451) with videos related to

Sort By:
Pageof 46
Journal of the National Cancer Institute|April 20, 2006
Assessing risk: does this patient have prostate cancer?H Ballentine Carter
The Journal of Urology|March 2, 2019
Editorial CommentH Ballentine Carter
European Urology|July 15, 2014
Reducing prostate cancer deaths: unsupported speculation about the androgen deprivation hypothesisH Ballentine Carter
Journal of the National Cancer Institute. Monographs|December 29, 2012
Active surveillance for prostate cancer: an underutilized opportunity for reducing harmH Ballentine Carter
The Johns Hopkins Medical Letter Health After 50|January 31, 2008
Consultation corner. Prostate screening: refining what PSA levels meanH Ballentine Carter
Urology|February 1, 2003
Informed consent for prostate-specific antigen screeningH Ballentine Carter
Urology|July 2, 2009
Editorial commentH Ballentine Carter
Oncology (Williston Park, N.Y.)|April 8, 2014
Baseline PSA testing for men in their 40s: testing in average-risk men aged 40 to 50 years should not be routinely performedH Ballentine Carter
Current Opinion in Urology|February 19, 2015
Aligning evidence and practice: future research needs to increase utilization of active surveillance for favorable risk prostate cancerH Ballentine Carter
The Journal of Urology|August 21, 2002
Re: long-term followup after laparoscopic radical nephrectomyH Ballentine Carter
Pageof 46